Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes

被引:81
作者
Azukizawa, H
Kosaka, H
Sano, S
Heath, WR
Takahashi, I
Gao, XH
Sumikawa, Y
Okabe, M
Yoshikawa, K
Itami, S
机构
[1] Osaka Univ, Grad Sch Med, Dept Dermatol, Course Mol Med, Suita, Osaka 5650871, Japan
[2] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia
[3] Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan
[4] China Med Univ, Hosp 1, Dept Dermatol, Shenyuang, Peoples R China
[5] Osaka Univ, Genome Informat Res Ctr, Osaka, Japan
关键词
cross-priming; CTL; keratinocyte; OVA; transgenic;
D O I
10.1002/eji.200323630
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Transgenic mice were generated to establish an animal model for T-cell-mediated autoimmune skin disease. A membrane-bound form of OVA (mOVA) was specifically expressed under the control of the keratin 5 (K5) promoter in the epidermal and hair follicular keratino-cytes of mice. Syngeneic, wild-type mice rejected the skin grafts of K5-mOVA mice with the generation of OVA-specific CTL. To study the CTL response against K5-mOVA skin, we used OT-I transgenic mice, which produce K-b-restricted, OVA-specific CD8(+) T cells. Accelerated rejection of K5-mOVA skin was demonstrated when transplanted onto OT-I mice. Furthermore, OT-I cells, when adoptively transferred into K5-mOVA mice, underwent activation and vigorous proliferation in the skin-draining lymph nodes. A bone-marrow-reconstitution assay demonstrated that K-b presentation by bone-marrow-derived cells, but not epithelial cells, was required for this response, indicating that cross-priming was the basis for immunity in this model. Finally, transferred OT-O cells, activated by cross-priming, targeted the skin of K5-mOVA mice, resulting in development of skin lesions that were reminiscent of toxic epidermal necrolysis. We conclude that our system provides a useful model for autoimmune skin diseases and will aid understanding of the pathomechanism of drug eruption, viral exan-therna, and graft-versus-host disease.
引用
收藏
页码:1879 / 1888
页数:10
相关论文
共 30 条
[1]   CHANGES IN CD45 ISOFORM EXPRESSION ACCOMPANY ANTIGEN-INDUCED MURINE T-CELL ACTIVATION [J].
BIRKELAND, ML ;
JOHNSON, P ;
TROWBRIDGE, IS ;
PURE, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6734-6738
[2]   CD8+lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: Further similarities with toxic epidermal necrolysis [J].
Correia, O ;
Delgado, L ;
Barbosa, IL ;
Domingues, JC ;
Azevedo, R ;
Vaz, CP ;
Pimentel, P .
DERMATOLOGY, 2001, 203 (03) :212-216
[3]   CD8+ but not CD8- dendritic cells cross-prime cytotoxic T cells in vivo [J].
den Haan, JMM ;
Lehar, SM ;
Bevan, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (12) :1685-1695
[4]   Autoimmune diseases: genes, bugs and failed regulation [J].
Ermann, J ;
Fathman, CG .
NATURE IMMUNOLOGY, 2001, 2 (09) :759-761
[5]  
Ganss R, 2002, CANCER RES, V62, P1462
[6]   Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice [J].
Gilhar, A ;
Ullmann, Y ;
Berkutzki, T ;
Assy, B ;
Kalish, RS .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (01) :62-67
[7]   Cross-presentation, dendrttic cells, tolerance and immunity [J].
Heath, WR ;
Carbone, FR .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :47-64
[8]   PREDOMINANCE OF EPIDERMAL CD8+ T-LYMPHOCYTES IN BULLOUS CUTANEOUS REACTIONS CAUSED BY BETA-LACTAM ANTIBIOTICS [J].
HERTL, M ;
BOHLEN, H ;
JUGERT, F ;
BOECKER, C ;
KNAUP, R ;
MERK, HF .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1993, 101 (06) :794-799
[9]   T-CELL RECEPTOR ANTAGONIST PEPTIDES INDUCE POSITIVE SELECTION [J].
HOGQUIST, KA ;
JAMESON, SC ;
HEATH, WR ;
HOWARD, JL ;
BEVAN, MJ ;
CARBONE, FR .
CELL, 1994, 76 (01) :17-27
[10]   Constitutive class I-restricted exogenous presentation of self antigens in vivo [J].
Kurts, C ;
Heath, WR ;
Carbone, FR ;
Allison, J ;
Miller, JFAP ;
Kosaka, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :923-930